To date, only SGLT2 inhibitors have produced a robust and significant reduction of heart failure risk, which has remained of similar magnitude regardless of a history of heart failure or established cardiovascular diseases [24, 25, 42, 43]. This evidence concerns the gene SLC5A2 and cardiovascular disorder.